CommercialCoverageHigh impact
Hyperbaric Oxygen Therapy (HBOT) (CPB 0172, reviewed 2026-04-21)
Aetna·Plastic Surgery, General Surgery, Orthopedics +9 more·Medical Policy
Effective date
Apr 21, 2026
We identified it
Aug 18, 2026
Summary
Aetna has issued a comprehensive Clinical Policy Bulletin (CPB 0172) establishing medical necessity criteria and treatment session limits for Hyperbaric Oxygen Therapy (HBOT) across 23+ approved conditions. This policy defines specific indications, maximum session counts, documentation requirements (including photographic evidence with ruler measurements), and healing progress benchmarks (measurable improvement required within any 30-day treatment period or therapy is deemed not medically necessary). The policy is effective immediately as of April 21, 2026.
Action Required
IMMEDIATELY: (1) Billing team must update prior authorization workflows in billing software to reflect the 23+ covered HBOT indications with their specific session limits (e.g., acute CO poisoning: 1-3 sessions; diabetic lower extremity wounds: up to 40-60 sessions; radiation necrosis: up to 40+10 sessions). (2) Coding/documentation staff must establish internal checklists requiring providers to submit with HBOT claims: specific diagnosis/indication, photographic documentation with ruler (for wound cases), evidence of 30+ days standard care failure (for diabetic wounds), imaging documentation (for arterial insufficiency), and proof of prior treatment attempts (e.g., 6 weeks antibiotics for osteomyelitis). (3) Update denial response templates to reference the 30-day healing progress requirement—if no measurable healing demonstrated within 30 days, deny continuation and communicate to providers that further sessions are not medically necessary per policy. (4) Configure system alerts: for wound-related HBOT (diabetic ulcers, osteomyelitis, grafts, necrotizing infections), require photographic evidence submission after every 15 treatments AND at minimum every 30 days; flag claims lacking this documentation for denial. (5) Providers and wound care coordinators must be notified via bulletin that effective 2026-04-21, HBOT claims lacking required documentation (especially photographic evidence for wound cases and proof of standard care failure for diabetic wounds) will be denied. (6) For refractory osteomyelitis cases, ensure documentation confirms Stage 3 or 4 diagnosis via X-ray/MRI/culture AND at least 6 weeks parenteral antibiotics AND at least one surgical debridement attempt before authorizing HBOT. Failure to implement these requirements will result in high claim denial rates and provider disputes.